Table 2.
Association of Cancer History with Prevalence of Anticoagulant Prescription Fills in Patients with Nonvalvular Atrial Fibrillation: MarketScan 2009–2014 (N=388,045)
| Subgroup | Prescription Fill (%) | Primary Analysis RR (95%CI)*† |
Propensity-Score Matched RR (95%CI)*‡ | |
|---|---|---|---|---|
| Cancer | No Cancer | |||
| All Cancer | (N = 64,016) | (N = 324,029) | ||
| Any | 31 | 35 | 0.89 (0.88, 0.90) | 0.89 (0.88, 0.90) |
| Colon | 28 | 34 | 0.86 (0.83, 0.89) | 0.87 (0.84, 0.90) |
| Lung | 24 | 34 | 0.73 (0.71, 0.76) | 0.75 (0.72, 0.77) |
| Breast§ | 33 | 31 | 1.02 (0.99, 1.05) | 1.03 (1.01, 1.06) |
| Prostate** | 35 | 36 | 0.95 (0.93, 0.97) | 0.96 (0.94, 0.98) |
| Pancreas | 18 | 34 | 0.60 (0.52, 0.68) | 0.61 (0.53, 0.69) |
| Hematologic | 28 | 34 | 0.85 (0.83, 0.88) | 0.87 (0.84, 0.90) |
| Active Cancer | (N = 26,450) | (N = 324,029) | ||
| Any | 29 | 35 | 0.85 (0.83, 0.86) | 0.85 (0.83, 0.87) |
| Colon | 26 | 34 | 0.80 (0.76, 0.84) | 0.81 (0.77, 0.85) |
| Lung | 23 | 34 | 0.72 (0.69, 0.75) | 0.73 (0.69, 0.76) |
| Breast§ | 32 | 31 | 1.02 (0.98, 1.06) | 1.03 (0.99, 1.07) |
| Prostate** | 32 | 36 | 0.89 (0.86, 0.92) | 0.91 (0.87, 0.94) |
| Pancreas | 19 | 34 | 0.59 (0.50, 0.70) | 0.60 (0.51, 0.72) |
| Hematologic | 26 | 34 | 0.78 (0.75, 0.82) | 0.80 (0.76, 0.84) |
| Remote Cancer | (N = 37,556) | (N = 324,029) | ||
| Any | 32 | 35 | 0.91 (0.90, 0.92) | 0.91 (0.90, 0.93) |
| Colon | 31 | 35 | 0.89 (0.85, 0.93) | 0.90 (0.86, 0.95) |
| Lung | 25 | 35 | 0.74 (0.70, 0.78) | 0.75 (0.71, 0.79) |
| Breast§ | 33 | 31 | 1.00 (0.97, 1.04) | 1.02 (0.98, 1.05) |
| Prostate** | 36 | 37 | 0.96 (0.94, 0.99) | 0.97 (0.94, 0.99) |
| Pancreas | 18 | 34 | 0.58 (0.47, 0.70) | 0.58 (0.48, 0.71) |
| Hematologic | 31 | 35 | 0.91 (0.87, 0.94) | 0.92 (0.88, 0.96) |
Comparison between cancer and no cancer.
Relative risk of anticoagulant prescription fills for patients with vs. without cancer. Adjusted for cardiology involvement, age, sex, heart failure, hypertension, diabetes, stroke, myocardial infarction, kidney disease, liver disease, bleeding history, alcohol use, antiplatelet agents, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, amiodarone, digoxin, CHA2DS2-VASc, and HAS-BLED.
Results of 1:2 propensity-matched analysis for patients with and without cancer. Propensity score was computed using multivariable logistic regression with the following variables: age, sex, heart failure, hypertension, diabetes, stroke, myocardial infarction, kidney disease, liver disease, bleeding history, alcohol use, antiplatelet agents, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, amiodarone, digoxin, CHA2DS2-VASc, and HAS-BLED (N=189,220).
Analysis limited to women.
Analysis limited to men.
CHA2DS2-VASc=congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–75 years, and sex category; CI=confidence interval; HAS-BLED=hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age >65 years), drugs/alcohol concomitantly; RR=relative risk.